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Abstract
Candidaemia/invasive candidiasis (C/IC) is the most frequently occurring invasive fungal infection worldwide, with a particularly strong
impact and high incidence in the intensive-care unit, where there is a need for new treatment options and strategies. The echinocandin
anidulafungin has broad in vitro activity against a wide range of Candida species, along with favourable pharmacokinetics that allow admin-
istration in hepatic and renal impairment and with any comedication without the need for dose adjustments. The efﬁcacy and safety of
anidulafungin for the treatment of C/IC were demonstrated in a number of clinical studies and by some limited data from clinical prac-
tice. In a randomized comparative trial for the treatment of C/IC in adults, 76% of patients receiving anidulafungin and 60% of those
given ﬂuconazole were treated successfully (95% CI for difference: 4–27; p 0.01). Post hoc analyses suggest that anidulafungin is signiﬁ-
cantly more effective than standard-dose ﬂuconazole for the treatment of candidaemia in critically ill patients. Anidulafungin is generally
well tolerated, with commonly reported side effects including headache, hypokalaemia, gastrointestinal symptoms, abnormal liver func-
tion test results, and rash. In pharmaco-economic analyses, anidulafungin compared favourably with ﬂuconazole (in terms of overall costs
and hospital resource use) as well as with other echinocandins. Echinocandins, including anidulafungin, are now generally recommended
as ﬁrst-line therapy in moderately to severely ill patients, those with prior azole exposure, and patients with C/IC caused by Candida
glabrata or Candida krusei.
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Introduction
Candidaemia/invasive candidiasis (C/IC) is the most fre-
quently occurring invasive fungal infection worldwide and, in
terms of incidence and outcomes, has a particularly heavy
impact on intensive-care unit (ICU) patients [1–5]. The inci-
dence of invasive Candida infections has risen along with the
increased use of intravenous catheters, broad-spectrum anti-
biotics, parenteral nutrition, immunosuppressive therapy, and
invasive procedures, all of which are important relevant risk
factors [6–8] (Table 1). In the USA, candidaemia is the third
and fourth most common nosocomial bloodstream infection
in ICUs and non-ICU wards, respectively [10], and in Europe
the rate of candidaemia ranges from 0.17 to 20 per 1000
hospital admissions, depending on country and patient popu-
lation [8,11,12]. Incidence rates of invasive Candida infections
appear to have stabilized in the USA during the period
1996–2003, but may be increasing in some European nations
[2,8,9,13–18]. Incidence rates vary signiﬁcantly according to
speciﬁc patient populations. In solid organ transplant patients,
for example, both the prevalence of invasive fungal infections
and the associated mortality depend on the speciﬁc type of
organ transplant, with invasive candidiasis (IC) being most
common in liver transplant patients [19]. The incidence of
candidaemia in the ICU is ﬁve to 10 times higher than among
other hospitalized patients, and over 100 times greater than
in the general population [1]. Approximately 10% of ICU
patients are affected by IC, with up to 15% of nosocomial
infections in this population being attributable to Candida
species [20]. Furthermore, in critically ill patients, C/IC
generally results in higher mortality rates. Crude mortality
rates remain substantial, ranging from 38% to 62% in Europe
[5,12,20–22]; fatality rates of up to 75% have been reported
in the USA [13]. A recent study in patients at a single UK
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hospital estimated the mortality attributable to candidaemia
as 35% [23], and a similar study in North American patients
reported a rate of 49% [24]. Candidaemia is also associated
with considerable increases in overall treatment cost and
length of stay in the ICU [2,23,25–28].
Outcomes of C/IC appear to vary signiﬁcantly according
to patient age as well as the causative Candida species; the
highest mortality rates are observed with Candida krusei, fol-
lowed by Candida tropicalis and Candida glabrata [6,12]. Spe-
cies distribution and antifungal susceptibility both show
considerable geographical variation, underscoring the impor-
tance of understanding local epidemiology to the effective
management of IC [1,8,29–31]. Although Candida albicans
remains the predominant cause of C/IC, the frequency of
infections caused by non-albicans species is rapidly increasing
across the globe [1,6,8,9,32,33]. In fact, some studies report
that less than half of all cases in the USA and Europe are
now caused by C. albicans [6,33]; the incidence rate may fall
below 20% at some individual institutions [31]. This is a
worrying trend, as some of the emerging species are associ-
ated with intrinsic or acquired resistance to ﬂuconazole
[9,13,30–32], which is the mainstay of candidaemia treat-
ment, as well as with higher mortality rates [6]. Along with
geographical differences, certain underlying risk factors may
also contribute to variations in epidemiology [6,8,9]. For
instance, C. glabrata candidaemia seems more common in
older patients and solid organ transplant recipients, whereas
risk factors for C. krusei include the prior use of antifungal
agents, haematological malignancy, and neutropenia (Table 1)
[6].
Treatment outcomes are also heavily dependent on the
appropriate use of available therapy options. As compared
with other bloodstream infections, fungaemias appear to be
associated with a particularly high rate of inappropriate ﬁrst-
line treatment, mainly in the form of delay or even complete
omission of antifungal therapy [13]. This situation is a serious
cause for concern, as a number of studies have demon-
strated that early, adequate treatment of C/IC signiﬁcantly
improves patient survival [34–37]. The early treatment of IC
is mainly impeded by a lack of rapid and sensitive diagnostics.
Much ongoing work is therefore aiming to develop risk fac-
tor assessments for the identiﬁcation of those patients who
would proﬁt most from antifungal prophylaxis or early treat-
ment [13,38–40].
Antifungal prophylaxis may reduce candidaemia incidence
rates as well as mortality in selected populations
[13,39,41,42], and thus seems a very attractive management
approach, albeit one that is still under discussion for non-
neutropenic ICU patients [39,42]. Routine ﬂuconazole pro-
phylaxis in the ICU may be associated with a signiﬁcant
increase in non-albicans, azole-resistant fungaemia, and should
therefore be considered carefully; antifungal prophylaxis may
also result in avoidable drug-related toxicity [3,42]. Some
authors recommend that triazole prophylaxis for the preven-
tion of invasive Candida infections should be reserved only
for particularly high-risk ICU populations, such as patients
undergoing repeated abdominal surgery for tertiary peritoni-
tis and/or acute pancreatitis [43]. Pre-emptive therapy, i.e.
early initiation of treatment before C/IC has been diagnosed
with certainty, may thus be a more appropriate alternative
to chemoprophylaxis, especially when combined with infec-
tion control measures [13,42,43]. Pre-emptive therapy is
based on a combination of risk factor evaluations and
assessment of diagnostic markers (e.g. Candida colonization,
b-D-glucan, procalcitonin, fungal DNA, mannan/anti-mannan
antibodies, and Candida germ-tube antibodies) [44–46], and
as such, encompasses a variety of different strategies aimed
at selecting patients suitable for early treatment [41–43,47].
For example, a ‘Candida score’ integrating the presence of
risk factors and the extent of Candida colonization has been
shown to be a good predictor of IC [45]. A somewhat sim-
pler validated risk-score model was also recently published,
and may constitute a useful tool for the rapid identiﬁcation
of patients at increased likelihood of developing candidaemia
[38]. Another early therapy approach is termed empirical
treatment, and denotes the administration of antifungals to
patients symptomatic for an infection but without microbio-
logical conﬁrmation [42]. However, empirical treatment for
C/IC remains questionable. For example, in a recent large,
placebo-controlled, randomized trial in ICU patients, unre-
solved fever refractory to broad-spectrum antibiotics was
used as an indication to initiate ﬂuconazole therapy. The trial
TABLE 1. Common risk factors for invasive Candida infec-
tions [6,8,9]
Candida species Risk factors
Candida
species overall
Invasive surgical procedures,
especially gastrointestinal surgery
Intravenous catheters
Total parenteral nutrition
Neutropenia
Immunosuppressive therapy
Use of broad-spectrum antibiotics
Cancer chemotherapy
Use of H2 blockers
Premature birth
Prolonged intensive-care unit stay
Renal failure/haemodialysis
Mucosal Candida colonization
Candida krusei Neutropenia
Corticosteroid therapy
Prior use of azole antifungals
Haematological malignancy
Stem cell transplantation
Candida glabrata Older age
Solid organ transplantation
Candida parapsilosis Recent surgery
Peripherally inserted central venous catheters
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demonstrated that this particular approach to empirical anti-
fungal treatment did not improve a composite outcome mea-
sure when compared with placebo [48]. The various
approaches proposed for early therapy have considerable
potential, but need to be reﬁned and validated in additional
clinical studies [41,47]. Regardless of the speciﬁc treatment
strategy, the relatively high incidence of C/IC, the substantial
associated mortality rates and the increasing prevalence of
ﬂuconazole resistance suggest the need for more effective
antifungals to manage this condition. In this respect, the echi-
nocandins (anidulafungin, caspofungin, and micafungin) appear
to hold particular promise.
Overview of anidulafungin
Anidulafungin is a novel broad-spectrum antifungal that is
indicated for the treatment of candidaemia and other forms
of IC in adult non-neutropenic patients [49] (see Table 2 for
a comprehensive overview of C/IC treatment options avail-
able in Europe). Like other members of the echinocandin
class, it is a potent and selective inhibitor of the fungal
enzyme b-(1,3)-D-glucan synthase, thus ultimately disrupting
the integrity of fungal cell walls. Anidulafungin exhibits potent
in vitro fungicidal activity against a wide range of Candida
species, including strains resistant to ﬂuconazole [29,58–61].
Like all the echinocandins, anidulafungin is less active against
Candida parapsilosis isolates [7,62–64], although in vitro it may
be more potent against this species than both caspofungin
and micafungin [65]. However, the clinical signiﬁcance of
these ﬁndings is unknown; in clinical trials for instance,
C. parapsilosis infection was not signiﬁcantly less responsive
to echinocandin treatment than invasive mycoses caused by
other Candida species [7,62,66–69]. For example, a pooled
analysis of two phase III clinical trials demonstrated that the
causative Candida species had no impact on 42-day survival
and clinical success for C/IC patients, whether treated
with caspofungin, micafungin, or liposomal amphotericin B
(L-AmB). Lack of catheter removal, APACHE II scores >20,
age ‡70 years, neutropenia, and corticosteroid treatment, on
the other hand, did negatively impact on both of these out-
come variables [70].
Anidulafungin was also shown to be active against C. albi-
cans and C. parapsilosis bioﬁlms in vitro and in animal studies,
a possible class effect of the echinocandins [71,72] (Long
et al., 20th ECCMID, 2010, Poster 1919). If this activity can
be conﬁrmed in clinical trials, echinocandins may emerge as
an effective management strategy for catheter-related candi-
daemia [72]. Echinocandins also exhibit a so-called post-anti-
fungal effect (PAFE), i.e. suppression of fungal growth after
limited exposure to an antifungal. An in vitro study comparing
the PAFE of anidulafungin against C. albicans with that of
ﬂuconazole, caspofungin and amphotericin B found that
anidulafungin generally produced prolonged PAFEs even at
TABLE 2. Currently available management options for invasive Candida infections
Agent Relevant licensed indications in Europe [49–57]
Echinocandins
Anidulafungin Treatment of invasive candidiasis in adult non-neutropenic patients
Caspofungin 1. Treatment of invasive candidiasis in adult or paediatric patients
2. Empirical therapy for presumed Candida infections in febrile, neutropenic adult or paediatric patients
Micafungina 1. Treatment of invasive candidiasis in adult or paediatric patients (including neonates)
2. Prophylaxis of Candida infection in adult or paediatric patients undergoing allogeneic haematopoietic stem cell transplantation or
who are expected to have neutropenia
Polyenes
Conventional amphotericin B Treatment of disseminated candidiasis
Amphotericin B lipid complex Treatment of severe invasive candidiasis
Liposomal amphotericin B 1. Treatment of severe systemic and/or deep mycoses (including disseminated candidiasis) where toxicity (particularly nephrotoxicity)
precludes the use of conventional systemic amphotericin B in effective dosages
2. Empirical treatment of presumed fungal infections (including disseminated candidiasis) in febrile neutropenic patients where the
fever has failed to respond to broad-spectrum antibiotics and appropriate investigations have failed to deﬁne a bacterial or viral cause
Triazoles
Fluconazole 1. Treatment of systemic candidiasis, including candidaemia, disseminated candidiasis, and other forms of invasive candidal infection
2. Prophylaxis of fungal infections in immunocompromised patients considered to be at risk as a consequence of neutropenia
following cytotoxic chemotherapy or radiotherapy, including bone marrow transplant patients
Posaconazole 1. Prophylaxis of invasive fungal infections in high-risk patients receiving remission-induction chemotherapy for acute myelogenous
leukaemia or myelodysplastic syndromes expected to result in prolonged neutropenia and who are at high risk of developing invasive
fungal infections
2. Prophylaxis of invasive fungal infections in high-risk haematopoietic stem cell transplant recipients who are undergoing high-dose
immunosuppressive therapy for graft-versus-host disease
Voriconazole 1. Treatment of candidaemia in non-neutropenic patients
2. Treatment of ﬂuconazole-resistant serious invasive Candida infections (including Candida krusei)
Some of these agents are also licensed for the treatment of other invasive fungal diseases or for non-invasive Candida infections.
aThe decision to use micafungin should take into account a potential risk for the development of liver tumours. Micafungin should therefore only be used if other antifungals
are not appropriate.
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concentrations below the MIC for this agent. In contrast,
ﬂuconazole did not result in a PAFE at any concentration,
and caspofungin produced only a very short (0–2 h) PAFE at
concentrations below its MIC; the PAFE of amphotericin B
also tended to have shorter durations at levels below the
MIC [73]. Caspofungin, anidulafungin and amphotericin B all
displayed a prolonged PAFE of >12 h when tested at concen-
trations above their MICs [73]. In contrast, some Candida
isolates may exhibit continued growth at echinocandin
concentrations well above the MICs for these agents; this
so-called Eagle effect (or paradoxical growth) differs accord-
ing to the Candida species and the speciﬁc echinocandin
agent. Although in vitro paradoxical growth appears to be
more frequent with caspofungin and micafungin than with
anidulafungin, the clinical signiﬁcance of this phenomenon
remains unknown [74,75].
The pharmacokinetics of anidulafungin, characterized in
healthy subjects, special populations and patients, allow for
once-daily, ﬁxed-dose intravenous (IV) administration in adult
patients. It is given at a loading dose of 200 mg on the ﬁrst
day, followed by 100 mg daily thereafter [49,76]; the require-
ment for only once-daily administration is shared by all
currently available echinocandins [49–51]. However, anidula-
fungin has certain distinctive pharmacokinetic properties that
set it apart from other echinocandins (Table 3). Clearance of
anidulafungin occurs through slow chemical degradation, and
the resulting non-active primary metabolite appears to be
further degraded by plasma peptidases. There is no evidence
of hepatic metabolism mediated by cytochrome P450, nor
does anidulafungin appear to be an inhibitor or inducer of
the cytochrome P450 isozymes that are commonly involved
in drug metabolism [78]. There is also only negligible renal
involvement in the metabolism of anidulafungin, which is
almost exclusively eliminated through the faeces (up to 90%
as degradation products), presumably via biliary excretion
[78]. Finally, the parent drug is not a substrate for organic
anion-transporting protein or P-glycoprotein, both of which
are key transporters involved in the biliary elimination of
drugs; excretion of anidulafungin into the bile therefore
probably occurs via passive diffusion (Inskeep et al., 18th
ECCMID, 2008, Poster 1049). The lack of hepatic and renal
involvement in anidulafungin metabolism was further con-
ﬁrmed by results of pharmacokinetic studies in renally or
hepatically impaired populations [79]. Unlike the other echi-
nocandins, anidulafungin can therefore be administered with-
out dose adjustments to patients with any degree of renal/
hepatic insufﬁciency, and also does not require dose adjust-
ments with any concomitant drugs [49,78,79]. These proper-
ties make anidulafungin particularly suited to the treatment
of C/IC in ICU patients [80–82], who tend to present with
organ dysfunction and/or multiple comedications. In this con-
text, it should be noted that therapy with the echinocandin
micafungin requires close monitoring of liver function
(because of the potential risk of liver tumour development)
and should be conducted following a careful risk–beneﬁt
evaluation, particularly in patients with severe liver function
TABLE 3. Comparison of pharmacokinetic parameters and properties between the currently available echinocandins
[49–51,77]
Anidulafungin Caspofungin Micafungin
Key pharmacokinetic
parameters/properties
Intravenous administration only Intravenous administration only Intravenous administration only
Linear pharmacokinetics Moderate non-linear pharmacokinetics Linear pharmacokinetics
>99% plasma protein binding 92.4–96.5% plasma protein binding >99% plasma protein binding
Vss 30–50 L Vss unknown Vss 18–19 L
T1/2 40–50 h
a T1/2 9–11 h
b T1/2 10–17 h
a
CL 1 L/h CL 10–12 mL/min CL 0.15–0.3 mL/min/kg
Biotransformation: occurs via slow
chemical degradation and
subsequent metabolism by plasma peptidases;
no hepatic involvement
Biotransformation: occurs via spontaneous
degradation and subsequent
peptide hydrolysis and N-acetylation
Biotransformation: some involvement of
hepatic cytochrome P450 enzymes
Elimination: mainly via biliary excretion;
negligible renal clearance (<1%)
Elimination: about 40% of total dose
eliminated via urine
Elimination: primarily non-renal
Use in renal/hepatic
impairment
No dose adjustments for any degree of
hepatic impairment
No dose adjustments for any degree of
renal impairment
No dose adjustments for mild hepatic impairment;
dose adjustments for moderate hepatic
impairment; no recommendation for severe
hepatic impairment
No dose adjustments for any degree of
renal impairment
No dose adjustments for mild to moderate
hepatic impairment; no recommendation
for severe hepatic impairment
No dose adjustments for any degree of
renal impairment
Drug–drug
interactions
None known Closely monitor liver enzymes with
concomitant cyclosporin A
Adjustment of concomitant tacrolimus dosage
mandatory based on tacrolimus plasma levels
Increase caspofungin dosage with concomitant
efavirenz, nevirapine, rifampicin,
dexamethasone, phenytoin or carbamazepine
Sirolimus, nifedipine and itraconazole
dosage should be decreased in case of
observed toxicity
Vss, volume of distribution at steady state; T1/2, half-life; CL, total clearance.
aTerminal elimination half-life.
bb-Phase half-life (plasma concentrations decline in a polyphasic manner).
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impairment or certain chronic liver diseases, or those receiv-
ing concomitant hepatotoxic agents [50].
Clinical efﬁcacy and safety
Initial clinical studies indicating the efﬁcacy and safety of ani-
dulafungin in the treatment of C/IC included a phase II, dose-
ranging trial in this setting, which showed microbiological
eradication rates (but not treatment-related adverse events)
to be dose-dependent [83]. On the basis of the results of
that study, phase III trials of anidulafungin for C/IC, including
that caused by C. parapsilosis, were suggested, using a 100-mg
maintenance dose [69,83]. Such a trial was subsequently con-
ducted in the form of a randomized, controlled, double-blind
comparison of anidulafungin with ﬂuconazole for the ﬁrst-line
therapy of documented C/IC [62]. Participants were
‡16 years of age and had at least one blood or tissue culture
positive for Candida within 96 h prior to enrolment. Another
inclusion criterion was the presence of one or more of the
following: fever, hypothermia, hypotension, local signs and
symptoms of IC, and/or radiological ﬁndings of IC. Key
exclusion criteria comprised prior azole prophylaxis, C. krusei
infection, refractory C/IC, and a diagnosis of Candida osteo-
myelitis, endocarditis, or meningitis. Eligible patients were
randomized to either IV anidulafungin (200 mg on day 1, and
100 mg daily thereafter) or IV ﬂuconazole (at the generally
recommended dose of 800 mg on day 1, and 400 mg daily
thereafter) in a 1 : 1 ratio. After 10 days of IV therapy,
patients were allowed to switch to oral ﬂuconazole (400 mg
daily) if they had been afebrile for at least 24 h, blood cul-
ture was negative for Candida, and they had shown clinical
improvement. Antifungal treatment continued for at least
14 days after the ﬁrst negative blood culture and clinical
improvement of C/IC, for a maximum of 42 days. The pri-
mary efﬁcacy endpoint of the study was global response at
the end of IV therapy (EOIT) in the modiﬁed intention-to-
treat (MITT) population, i.e. those patients who received at
least one dose of study drug and had conﬁrmed invasive Can-
dida infection at baseline. Death, lack of signiﬁcant clinical
improvement, persistent or recurrent C/IC or any indetermi-
nate response were considered as treatment failure. An
overview of this trial and of other key studies evaluating ech-
inocandins for the therapy of C/IC is presented in Table 4.
Of 261 enrolled patients, 245 were included in the MITT
population; of these, 127 received anidulafungin and 118
TABLE 4. Summary of major comparative phase III trials evaluating the echinocandins in candidaemia/invasive candidiasis
(C/IC)
Anidulafungin
(Reboli et al. 2007) [62]
Caspofungin
(Mora-Duarte et al. 2002) [84]
Micafungin
(Kuse et al. 2007) [85]
Study design Double-blind, randomized, multinational,
non-inferiority/superiority study
Double-blind, randomized, multinational,
non-inferiority/superiority study
Double-blind, randomized, multinational,
non-inferiority study
Patient population Adults (>16 years) with conﬁrmed C/IC
within 96 h prior to enrolment
Adults (>18 years) with conﬁrmed C/IC within
96 h prior to enrolment
Adults (>16 years) with conﬁrmed C/IC
within 96 h prior to enrolment
Dose Anidulafungin IV 100 mg/day
(loading dose 200 mg on day 1)
After ‡10 days, patients could be
switched to oral ﬂuconazole 400 mg/day,
under certain conditions
Caspofungin IV 50 mg/day
(loading dose 70 mg on day 1)
After ‡10 days, patients could be
switched to oral ﬂuconazole
400 mg/day, under certain conditions
Micafungin IV 100 mg/day (2 mg/kg for
patients weighing <40 kg). Could be
increased up to 200 mg/day if needed
Comparator agent Fluconazole IV 400 mg/day
(loading dose 800 mg on day 1)
After ‡10 days, patients could be
switched to oral ﬂuconazole 400 mg/day,
under certain conditions
Conventional AmB IV
Non-neutropenic patients: 0.6–0.7 mg/kg/day
Neutropenic patients: 0.7–1.0 mg/kg/day
After ‡10 days, patients could be
switched to oral ﬂuconazole
400 mg/day, under certain conditions
L-AmB 3 mg/kg/day. Could be increased
up to 5 mg/kg/day if needed
Treatment duration 14–42 days, for ‡14 days after a negative
blood culture and improvement in
signs/symptoms
Not speciﬁed, but 14 days after last
positive blood culture
14–28 days (up to 56 days in cases of chronic
disseminated candidiasis, Candida
osteomyelitis or Candida endocarditis)
Primary efﬁcacy
endpoint
Global response (deﬁned as both
clinical and microbiological success)
at the end of IV treatment in the
MITT population
Global response (deﬁned as both clinical
and microbiological success)
at the end of IV treatment in the
MITT population
Global response (deﬁned as both clinical
and microbiological success) at the end of
treatment in the PP population
Patient numbersa Anidulafungin: 127
Fluconazole: 118
Caspofungin: 109
AmB: 115
Micafungin: 202
L-AmB: 190
Primary efﬁcacy
results
Anidulafungin: 75.6%
Fluconazole: 60.2%
(95% CI for difference: 3.9–27.0)
Caspofungin: 73.4%
AmB: 61.7%
(95.6% CI for difference: )0.7 to 26.0)b
Micafungin: 89.6%
L-AmB: 89.5%
(95.6% CI for difference: )5.3 to 6.7)c
All-cause mortality Anidulafungin: 23%
Fluconazole: 31%
(p 0.13)
Caspofungin: 34%
AmB: 30%
(p 0.53)
Micafungin: 40%d
L-AmB: 40%d
AmB, amphotericin B; IV, intravenous; L-AmB, liposomal amphotericin B; MITT, modiﬁed intention-to-treat; PP, per-protocol.
aIn the primary efﬁcacy population of each trial.
bAfter adjustment for neutropenic status and APACHE II score.
cAfter adjustment for neutropenic status.
dCalculated on the basis of numbers in the intention-to-treat population, including the 12-week follow-up period.
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ﬂuconazole. Treatment arms did not differ in patient demo-
graphics, baseline Candida species, treatment duration, or fre-
quency and exposure to oral ﬂuconazole. The most common
causative pathogen was C. albicans (62%), followed by C. glab-
rata, which was isolated in 16% and 25% (p 0.08) of those in
the anidulafungin and ﬂuconazole groups, respectively.
Ninety-six per cent of all isolates were ﬂuconazole-suscepti-
ble. At EOIT, there was a signiﬁcantly greater global
response rate with anidulafungin (76%) than with ﬂuconazole
(60%; p 0.01); the difference was 15 percentage points
(95% CI 4–27). A number of statistical analyses all failed to
demonstrate the potential inﬂuence of a centre effect on the
primary outcome [62]. Anidulafungin also showed better efﬁ-
cacy at EOIT and at 2 weeks after EOIT, and was non-infe-
rior at 6 weeks post-EOIT. There was no statistically
signiﬁcant difference in mortality rates between ﬂuconazole
and anidulafungin (31% vs. 23%; p 0.13). It is of note that
approximately 20% of patients in each arm had APACHE II
scores >20, and in this subpopulation the response rates
with anidulafungin and ﬂuconazole were similar [62]. A num-
ber of reports suggest that high baseline APACHE II scores
may negatively impact on mortality and the success of anti-
fungal therapy in patients with C/IC [86–88], which could
explain these ﬁndings.
In terms of causative pathogens, global responses with ani-
dulafungin at EOIT were highest for C. tropicalis (93%) and
lowest for C. glabrata (56%); C. parapsilosis, which exhibited
the highest MICs of anidulafungin, had an EOIT response rate
of 64%. It is of note that the global response rates against
C. albicans infections were remarkably different between the
two study treatments (81% for anidulafungin vs. 62% for
ﬂuconazole; p 0.02) [62]. Microbiological failure in patients
with C. albicans infection was signiﬁcantly lower with anidula-
fungin than with ﬂuconazole, whereas no signiﬁcant differ-
ences were evident in other baseline Candida infections [89].
Similar advantages in microbiological clearance were not
observed in clinical trials with other echinocandins [89].
These observations are important, considering that C. albi-
cans remains the most common pathogenic Candida species
overall [6,8,13].
Critically ill patients comprise another important patient
subgroup, and a post hoc analysis was therefore conducted to
compare the responses to anidulafungin and ﬂuconazole in
this population [90]. For the purposes of that analysis, three
groups of critically ill patients were identiﬁed from the origi-
nal trial [62]: those in the ICU at study entry (n = 89);
patients with APACHE II scores ‡15 (n = 113); and patients
with severe sepsis and organ dysfunction (n = 118) [90].
Global responses at EOIT were better with anidulafungin in
each of these subgroups, but the difference only reached
statistical signiﬁcance in the second group. Among those in
the ICU at study entry, global response rates were 63% and
45% for anidulafungin and ﬂuconazole, respectively (95% CI
for difference: )2% to 40%). Similarly, response rates in the
second group were 68% and 46% (95% CI for difference: 4–
40%), respectively, and they were 68% and 52% (95% CI for
difference: )2% to 34%) in the third group. Among patients
with multiple organ dysfunction (n = 45), global response
rates were 76% for anidulafungin and 30% for ﬂuconazole
(95% CI for difference: 21–73%). Across groups, no signiﬁ-
cant survival advantages at either day 14 or day 28 were
observed. The investigators concluded that anidulafungin was
signiﬁcantly more effective than ﬂuconazole for the treat-
ment of candidaemia in critically ill patients (deﬁned as either
those with sepsis and multiple organ dysfunction or those
with APACHE II scores ‡15) [90]. This observation lends
support to current guidelines [4,7,42] recommending echino-
candins as ﬁrst-line C/IC treatment in this population [90].
In conjunction with the main trial [62], an open-label, non-
comparative study was also conducted [77]. This additional
study was similar in design, but evaluated anidulafungin in
patients who were excluded from the main study because of
previous azole prophylaxis, known azole hypersensitivity,
treatment with medications contra-indicated with ﬂucona-
zole, and/or C. krusei infection. The resultant global response
rate at EOIT was 68% in the overall MITT population, with
global, clinical and microbiological success being sustained
from 2 to 6 weeks after treatment initiation [77]. Anidulafun-
gin thus appears to be effective in a wider patient population,
including those with C/IC after azole prophylaxis and
patients who are intolerant of azole therapy.
Anidulafungin presented with a very favourable safety and
tolerability proﬁle in all clinical studies [62,83]. Commonly
reported side effects with this agent are headache, hypokala-
emia, diarrhoea/vomiting/nausea, abnormal liver or kidney
function test results, rash/pruritis, ﬂushing, disorders of the
blood clotting system, and convulsions. Uncommon side
effects include cholestasis, injection site pain, hives, hyper-
glycaemia, hypertension, hot ﬂushes, and stomach pain [49].
In the randomized trial comparing anidulafungin and ﬂuconaz-
ole for C/IC, both agents resulted in similar numbers of
treatment-related adverse events (24% and 26% of patients,
respectively), including those of a serious nature. The major-
ity of all-causality adverse events were mild to moderate in
intensity [62]. Elevated liver function test ﬁndings related to
study treatment were observed in more patients on ﬂucona-
zole (7%) than anidulafungin (2%; p = 0.03). In addition,
signiﬁcantly more patients treated with ﬂuconazole than with
anidulafungin discontinued the study drug because of
adverse events (p 0.02); however, many of these side effects
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associated with ﬂuconazole may actually have been caused by
worsening clinical status rather than being true treatment-
related adverse events [62]. The safety of anidulafungin was
also assessed in hospitalized, neutropenic children aged 2–
17 years who were given anidulafungin empirically as part of
an open-label study [91]. Study participants (n = 24) received
either 0.75 mg/kg or 1.5 mg/kg IV anidulafungin daily. All
patients experienced at least one all-causality adverse event,
most of which were mild to moderate in severity; ﬁve
patients in each dosage group experienced serious adverse
events. No patients in the higher-dosage group experienced
adverse events that led to treatment discontinuation or that
were considered to be related to anidulafungin. In the
lower-dose group, four patients experienced anidulafungin-
related side effects, but none was serious or led to discon-
tinuation of the study drug. The authors concluded that, at
the doses studied, anidulafungin was well tolerated in neu-
tropenic paediatric patients at high risk for invasive fungal
infections [91]. It is of note that anidulafungin is currently
not indicated for use in children [49].
A recent meta-analysis of randomized clinical trials in C/IC
showed that echinocandins overall were non-inferior to
other pertinent antifungals, but exhibited a better safety pro-
ﬁle [89]. This analysis suggested superior efﬁcacy of anidula-
fungin over ﬂuconazole in terms of treatment and
microbiological success, despite the lack of signiﬁcant differ-
ences in survival rates. Comparative studies with other echi-
nocandins (but conducted against polyenes, not ﬂuconazole)
did not demonstrate any signiﬁcant differences in overall
treatment and microbiological failure. The authors pointed
out that ﬂuconazole should be avoided for empirical mono-
therapy in severely ill patients, in whom rapid microbiological
clearance of Candida is essential [89].
Use of anidulafungin in clinical practice
The body of data reporting on actual clinical experience with
anidulafungin remains limited, as this agent has only recently
become available. One relevant publication describes a retro-
spective cohort study evaluating anidulafungin in clinical prac-
tice at a large tertiary medical centre [92]. The study
included a total of 35 patients, 49% of whom received anidu-
lafungin for empirical antifungal treatment. Anidulafungin was
used to treat candidaemia or IC in 29% and 20% of patients,
respectively. Of 13 evaluable patients, 77% experienced a
favourable clinical outcome. However, one patient developed
breakthrough candidaemia caused by C. parapsilosis while on
anidulafungin. One patient reported an infusion-related reac-
tion; otherwise anidulafungin exhibited good tolerability,
including in patients receiving concomitant metronidazole.
The authors suggest that, on the basis of their clinical experi-
ence, anidulafungin may be particularly useful in patients with
hepatic dysfunction and those receiving concomitant medica-
tions that can interact with other echinocandins [92].
These properties may give anidulafungin somewhat of a
practical advantage over caspofungin and micafungin in
patient populations commonly affected by organ dysfunction
and/or receiving multiple concomitant drugs, such as ICU
patients. It should be noted, however, that the current evi-
dence does not indicate any signiﬁcant efﬁcacy and tolerabil-
ity differences among the echinocandins [89].
Cost considerations also play an increasingly important
role in determining the practical usefulness of medications. A
number of studies have shown that the overall expenses
associated with the treatment of C/IC are signiﬁcant and are
largely driven by hospitalization costs [25–28]. Although gen-
eric ﬂuconazole is relatively inexpensive, more effective ﬁrst-
line agents may thus not only improve clinical outcomes but
also offset some of the higher acquisition costs. This was
shown to be the case in a pharmaco-economic model com-
paring the cost-effectiveness of anidulafungin and ﬂuconazole
for the treatment of C/IC in Spain (Grau et al., 19th ECC-
MID, 2009, Poster 1745). The model was based on data
from the pivotal clinical trial [62], and indicated that overall
treatment costs with anidulafungin were slightly lower
(€37 240 vs. €37 327), despite its acquisition costs being
more than twice as high (€5780 vs. €2082). Furthermore,
anidulafungin treatment resulted in improved clinical success
(74% vs. 57%) and was associated with an incremental cost-
effectiveness ratio of )€505 per successfully treated patient
(Grau et al., 19th ECCMID, 2009, Poster 1745). Cost and
outcome data from the phase III trial in C/IC [62] were also
assessed from a US perspective [87] (Reboli et al., 19th
ECCMID, 2009, Poster 1746). The results of both analyses
suggest that anidulafungin signiﬁcantly improves clinical out-
comes among hospital inpatients in general and ICU patients
in particular, when compared with ﬂuconazole. In hospital-
ized patients overall, this was achieved while keeping total
treatment costs similar to those with ﬂuconazole (Reboli
et al., 19th ECCMID, 2009, Poster 1746). For patients in the
ICU at treatment initiation, anidulafungin exhibited a deﬁnite
but non-signiﬁcant trend towards lower costs, which was
driven by reductions in ICU and hospital lengths of stay.
After adjustment for baseline covariates, those ICU patients
who received anidulafungin as ﬁrst-line therapy for C/IC
gained a signiﬁcant advantage in the number of hospital-free
days (18.2 vs. 4.3 days; p 0.04) [87].
Another pharmaco-economic study compared the three
currently available echinocandins for the treatment of IC in a
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Spanish hospital setting. Anidulafungin therapy was found to
have a lower drug acquisition cost per episode (€6000) than
other echinocandins, for which costs are inﬂuenced by the
potential requirement for dose adjustments. Treatment costs
with caspofungin were reported to range from €4281 to
€7991, depending on the speciﬁc dose requirements based on
patient weight and hepatic function. Drug acquisition costs
with micafungin were estimated at either €6000 (using a
dose of 100 mg/day) or €10 741 (in cases where inadequate
response requires a dose increase to 200 mg/day). The
authors concluded that treating IC in adult, non-neutropenic
patients with anidulafungin was a cost-saving option, and also
allowed for better budget control (Garcia et al., 12th Annual
European Congress of the International Society for Pharmaco-
economics and Outcomes Research, 2009, PIN12).
Treatment guidelines and
recommendations
Current guidelines recommend either ﬂuconazole or an echi-
nocandin as the ﬁrst-line agent for targeted or empirical
therapy of C/IC in most adult non-neutropenic patients. The
guidelines also stress the importance of early initiation of
effective antifungal treatment to improve the odds of patient
survival [4,7,42]. The speciﬁc drug should be selected on the
basis of the antifungal susceptibility of the causative isolate,
the clinical status of the patient (including organ function),
prior antifungal treatment, and drug toxicity/tolerability [4].
These points are all addressed in the recent update of the
clinical guidelines of the Infectious Diseases Society of Amer-
ica for the management of invasive candidiasis, which take
into account novel options for antifungal therapy, particularly
the echinocandins [7]. The updated guidelines state that, in
non-neutropenic populations, the echinocandins (either ani-
dulafungin, caspofungin, or micafungin) should be preferred
in: (i) patients who are moderately to severely ill; (ii) patients
who have had recent azole exposure; and/or (iii) potential or
conﬁrmed infections caused by C. glabrata or C. krusei. In
cases of intolerance or unavailability of other antifungals,
conventional amphotericin B or lipid formulations of ampho-
tericin B are suggested as alternatives for ﬁrst-line therapy
[7]. Species identiﬁcation and susceptibility testing constitute
an important element of appropriate management, and
should form the basis for potential changes in the ﬁrst-line
drug or for switching from a parenteral agent to an oral
azole [4,7]. In particular, once the patient has become stable
and the causative Candida strain has been conﬁrmed as sus-
ceptible, step-down therapy from IV therapy to oral ﬂuco-
nazole or voriconazole should be initiated. First-line
ﬂuconazole is mainly recommended in non-neutropenic
patients without prior azole exposure who are less critically
ill, and in cases of C. parapsilosis infection. In neutropenic
patients, either an echinocandin or amphotericin B lipid for-
mulations are recommended for targeted therapy of docu-
mented candidaemia. Alternatively, ﬂuconazole may be used
in less critically ill neutropenic patients without prior azole
exposure. The removal of IV catheters is strongly recom-
mended for documented candidaemia in neutropenic
patients, especially in infections caused by C. parapsilosis, and
should be considered in non-neutropenic patients [4,7].
Therapy should be continued for 2 weeks after resolution of
candidaemia symptoms and clearance of Candida from the
bloodstream [7].
Similar treatment recommendations are made in a recent
European publication covering the management of C/IC in
adult, non-neutropenic ICU patients, which was based on a
literature review and an expert panel discussion [42]. The
authors suggest either echinocandins or polyenes whenever
there is a high probability of azole-resistant invasive Candida
infection (i.e. based on local epidemiology, colonization with
ﬂuconazole-resistant strains, or recent azole exposure). Echi-
nocandins are recommended as the preferred ﬁrst-line treat-
ment in haemodynamically unstable patients, i.e. patients in
septic shock or with sepsis complicated by organ dysfunction
[4,42]. In haemodynamically stable patients without organ
dysfunction, ﬂuconazole is suggested as a reasonable choice
for targeted therapy of IC; amphotericin B/lipid formulations
of amphotericin B, anidulafungin, caspofungin and voricona-
zole are listed as alternatives in this setting [42] (Fig. 1).
Guidelines have also been prepared by the European Confer-
ence for Infections in Leukaemia; these were last updated in
2009. These recommendations assign an AI level of evidence
(i.e. good evidence from one or more randomized, con-
trolled trials) to echinocandins, ﬂuconazole, voriconazole and
L-AmB as ﬁrst-line treatment for candidaemia prior to
species identiﬁcation, but advise against the use of azoles to
treat invasive Candida infections in patients with severe
illness and/or prior azole exposure. After species identiﬁca-
tion, echinocandins (along with L-AmB and conventional
amphotericin B) are given an AI grading against C. albicans
and a BI grading against C. glabrata and C. krusei. In haematol-
ogy patients, echinocandins, L-AmB and other lipid formula-
tions of amphotericin B are assigned a BII (i.e. moderate
evidence from one or more study) grading against all Candida
species, both before and after species identiﬁcation. The lat-
est European Conference for Infections in Leukaemia guide-
lines therefore recommend echinocandins as one of the
preferred treatment options for candidaemia in all clinical
settings [93].
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As the high mortality associated with C/IC [12,20,22–24]
can be signiﬁcantly reduced through early and adequate ﬁrst-
line treatment [34–37], new strategies to accurately identify
patients with early infections are desperately needed. Some
authors propose that such pre-emptive or empirical treat-
ment should be reserved for those patients with a high risk
(i.e. about 10–15%) of developing IC [40]. However, no sin-
gle predictive algorithm is available to accurately identify such
patients in the ICU. This currently leaves physicians with the
option to base decisions about the need for early antifungal
therapy on the frequent evaluation of clinical status and risk
factors in each critically ill patient [40], until proposed pre-
diction rules have been validated. Some authors have also
called for further research on the potential need for antifun-
gal dose adjustments in cases of haemodialysis, volume over-
load, and septic shock [4]; in this respect, it should be noted
that the pharmacokinetics of anidulafungin do not seem to
be altered by extended daily dialysis [94].
Conclusions
Anidulafungin is a useful option for the ﬁrst-line treatment of
C/IC, especially in critically ill patients, on the basis of its
demonstrated clinical efﬁcacy, good safety and tolerability,
and favourable pharmaco-economics. In vitro studies suggest
that anidulafungin may have better efﬁcacy against C. parapsilo-
sis than other currently available echinocandins, but the clini-
cal signiﬁcance of these ﬁndings is not known. Furthermore,
anidulafungin has an excellent drug interaction proﬁle, and is
the only echinocandin that does not require dose adjustments
with any concomitant drugs and any degree of renal or hepa-
tic impairment. Echinocandins, including anidulafungin, are
recommended as ﬁrst-line therapy in moderately to severely
ill patients, those with prior azole exposure, and those with
invasive infections caused by C. glabrata or C. krusei.
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